S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Price, News & Analysis

$2.18
-0.01 (-0.46%)
(As of 03/28/2024 ET)
Today's Range
$2.17
$2.30
50-Day Range
$1.41
$2.74
52-Week Range
$1.04
$2.86
Volume
2.85 million shs
Average Volume
924,398 shs
Market Capitalization
$147.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.10

CytomX Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
42.0% Upside
$3.10 Price Target
Short Interest
Bearish
5.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
0.40mentions of CytomX Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$73,200 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.21) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

258th out of 938 stocks

Pharmaceutical Preparations Industry

110th out of 417 stocks

CTMX stock logo

About CytomX Therapeutics Stock (NASDAQ:CTMX)

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CTMX Stock Price History

CTMX Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
J.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)
Recap: CytomX Therapeutics Q4 Earnings
CytomX Therapeutics's Earnings Outlook
BMY Oct 2024 45.000 put
BMY Aug 2024 60.000 call
BMY Apr 2024 52.000 put
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTMX
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.10
High Stock Price Target
$3.19
Low Stock Price Target
$3.00
Potential Upside/Downside
+42.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-570,000.00
Pretax Margin
3.28%

Debt

Sales & Book Value

Annual Sales
$101.21 million
Book Value
($0.71) per share

Miscellaneous

Free Float
63,049,000
Market Cap
$147.65 million
Optionable
Optionable
Beta
1.02
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Sean A. McCarthy DPHIL (Age 57)
    Chairman & CEO
    Comp: $1.03M
  • Mr. Lloyd A. Rowland Jr. (Age 67)
    J.D., Senior VP, General Counsel, Chief Compliance Officer & Secretary
    Comp: $608.72k
  • Mr. Jeffrey Landau B.S. (Age 46)
    M.B.A., Senior VP, Head of Strategy & Chief Business Officer
    Comp: $581.68k
  • Mr. Christopher W. Ogden (Age 40)
    Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer
  • Dr. Marcia P. Belvin Ph.D.
    Senior VP & Chief Scientific Officer
  • Dr. Chau Cheng M.B.A.
    Ph.D., Vice President of Investor Relations & Corporate Communications
  • Ms. Danielle Olander-Moghadassian
    Senior VP & Chief Human Resources Officer
  • Ms. Leslie Robbins
    Senior Vice President of Intellectual Property
  • Dr. Yu-Waye Chu M.D. (Age 56)
    Chief Medical Officer
  • Ms. Dawn Benson
    Senior Vice President of Quality & Product Manufacturing

CTMX Stock Analysis - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CTMX shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued twelve-month price targets for CytomX Therapeutics' shares. Their CTMX share price targets range from $3.00 to $3.19. On average, they anticipate the company's share price to reach $3.10 in the next year. This suggests a possible upside of 42.0% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2024?

CytomX Therapeutics' stock was trading at $1.55 on January 1st, 2024. Since then, CTMX stock has increased by 40.6% and is now trading at $2.18.
View the best growth stocks for 2024 here
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biotechnology company earned $17.59 million during the quarter, compared to analyst estimates of $18.53 million. During the same quarter in the previous year, the firm earned ($0.32) EPS.

What ETF holds CytomX Therapeutics' stock?

Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio.

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Bridgeway Capital Management LLC (0.65%), Assenagon Asset Management S.A. (0.60%), Formidable Asset Management LLC (0.46%), Congress Park Capital LLC (0.36%), Northern Trust Corp (0.20%) and GSA Capital Partners LLP (0.16%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTMX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners